MAY 9, 2019 - Use of statins before or after a diagnosis of colorectal cancer was linked with a lower risk of premature death, both from cancer and from other causes, in a Cancer Medicine analysis of published studies.
The meta-analysis included 14 studies involving 130,994 patients with colorectal cancer. Pre-diagnosis statin use was linked with a 15 percent lower risk of dying early from any cause and an 18 percent lower risk of dying from cancer. Post-diagnosis statin use was linked with a 14 percent lower risk of all-cause death and a 21 percent lower risk of cancer-specific death.
“Considering that statins are low-costed and wildly-used agents worldwide, we believe our updated meta-analysis can provide new insights into optimizing adjuvant treatment of colorectal cancer,” the authors wrote.
Full citation: Yue Li, Xingkang He, Yu’e Ding, Hongyang Chen, Leimin Sun. “Statins uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis” Cancer Medicine, 8 May 2019. <https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2151> DOI: 10.1002/cam4.2151.40892
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd., reproduced with permission.
- Copyright: © Saudi Medical Journal
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.